Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Antimyeloma Effect of the Simultaneous Inhibition of MCL-1 (with S63845) and BCL-2 (with Venetoclax) in the Presence of the Microenvironment

Esperanza M Algarín, MSc, Andrea Díaz-Tejedor, Pedro Mogollón, Susana Hernández-García, Luis Corchete, Laura San-Segundo, Montserrat Martín-Sánchez, Lorena González-Méndez, Marie Schoumacher, Sébastien Banquet, Laurence Kraus-Berthier, Ioana Kloos, Ensar Halilovic, Heiko Maacke, Norma C. Gutierrez, MD PhD, Maria-Victoria Mateos, MD PhD, Teresa Paíno, Mercedes Garayoa, Enrique M. Ocio, MD

Blood (2018) 132 (Supplement 1): 954.

https://doi.org/10.1182/blood-2018-99-116075

Published: 2018

Journal Articles

CRISPR/Cas9-Generated Models Uncover Therapeutic Vulnerabilities of Del(11q) Chronic Lymphocytic Leukemia Cells to Dual BCR and PARP Inhibition

Miguel Quijada Álamo, BSc, MSc, María Hernández-Sánchez, PhD, José Luis Ordóñez, PhD, Verónica Alonso Pérez, PhD, Ana E. Rodriguez, PhD, Ignacio García-Tuñón, PhD, Ana B Herrero, PhD, Laura San-Segundo, Michaela Gruber, MD PhD, Juan Luis García, PhD, Rocio Benito, PhD, Catherine J. Wu, MD, Jesús-María Hernández-Rivas, MD PhD

Blood (2018) 132 (Supplement 1): 948.

https://doi.org/10.1182/blood-2018-99-116080

Published: 2018

Journal Articles

Prognostic Implications of PIM-2 Expression in Samples from Patients with Chronic Lymphocytic Leukemia and Impact in the Sensitivity to the Pan-PIM Kinase Inhibitor PIM447

Ana Alicia López-Iglesias, Irena Misiewicz-Krzeminska, Ignacio Criado, Miguel Alcoceba, Susana Hernández-García, Laura San-Segundo, Lorena González-Méndez, Montserrat Martín-Sánchez, Esperanza M Algarín, Teresa Paíno, Mercedes Garayoa, Norma C Gutierrez, Maria-Victoria Mateos, Marcos González-Díaz, Enrique M Ocio

Blood (2015) 126 (23): 2923.

https://doi.org/10.1182/blood.V126.23.2923.2923

Published: 2015

Journal Articles

Mechanisms Underlying the Synergistic Interaction of Filanesib with Pomalidomide and Dexamethasone (FPD) in Multiple Myeloma

Susana Hernández-García, Laura San-Segundo, Lorena González-Méndez, Montserrat Martín-Sánchez, Luis A Corchete, Teresa Paíno, Ana Alicia López-Iglesias, Esperanza Macarena Algarín, Mercedes Garayoa, Brian Tunquist, Norma C Gutierrez, Maria-Victoria Mateos, MD PhD, Enrique M Ocio

Blood (2015) 126 (23): 1801.

https://doi.org/10.1182/blood.V126.23.1801.1801

Published: 2015

Journal Articles

Filanesib Primarily Initiates the Apoptotic Program By Activating Bax through a Calpain-Dependent Mechanism

Susana Hernández-García, Lorena González-Méndez, Irena Misiewicz-Krzeminska, Esperanza Macarena Algarín, Ana Alicia López-Iglesias, Laura San-Segundo, Montserrat Martín-Sánchez, Teresa Paíno, Norma C Gutierrez, Mercedes Garayoa, Brian Tunquist, Maria-Victoria Mateos, Enrique M Ocio

Blood (2015) 126 (23): 5353.

https://doi.org/10.1182/blood.V126.23.5353.5353

Published: 2015

Journal Articles

The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone

Ana Alicia López-Iglesias, Ana Belen Herrero, Laura San-Segundo, Susana Hernández-García, Lorena González-Méndez, Montserrat Martín-Sánchez, Esperanza M Algarín, Teresa Paino, Mercedes Garayoa, Thomas Mehrling, MD PhD, Norma C Gutierrez, Jesús F. San-Miguel, MD, Maria-Victoria Mateos, Enrique M. Ocio, MD PhD

Blood (2015) 126 (23): 5354.

https://doi.org/10.1182/blood.V126.23.5354.5354

Published: 2015

Journal Articles

The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies

Ana Alicia López-Iglesias, MD, Laura San-Segundo, Lorena González-Méndez, Susana Hernández-García, Daniel Primo, PhD, Mercedes Garayoa, PhD BS, Ana Belén Hernández, PhD, Teresa Paíno, PhD, Maria-Victoria Mateos, MD PhD, Yi Chen, Enrique M. Ocio, MD PhD, Thomas Mehrling, MD PhD

Blood (2014) 124 (21): 2100.

https://doi.org/10.1182/blood.V124.21.2100.2100

Published: 2014

Journal Articles

Filanesib (ARRY-520) Demonstrates Potent and Rapid Activity in Preclinical Models of MM, Dependent on Bcl-2 Family Expression, and Synergistic with Dexamethasone and IMiDs

Susana Hernández-García, Laura San-Segundo, Lorena González-Méndez, Teresa Paíno, PhD, Ana Alicia López-Iglesias, MD, Montserrat Martín-Sánchez, Mercedes Garayoa, PhD BS, Michael J Humphries, PhD, Brian Tunquist, PhD BS, Maria-Victoria Mateos, Enrique M Ocio, MD PhD

Blood (2014) 124 (21): 4710.

https://doi.org/10.1182/blood.V124.21.4710.4710

Published: 2014

Journal Articles

Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile

Bruno Paiva, Teresa Paino, Jose-Maria Sayagues, Mercedes Garayoa, Laura San-Segundo, Montserrat Martín, Ines Mota, María-Luz Sanchez, Paloma Bárcena, Irene Aires-Mejia, Luis Corchete, Cristina Jimenez, Ramon Garcia-Sanz, Norma C. Gutierrez, Enrique M. Ocio, Maria-Victoria Mateos, Maria-Belen Vidriales, Alberto Orfao, Jesús F. San Miguel

Blood (2013) 122 (22): 3591–3598.

https://doi.org/10.1182/blood-2013-06-510453

Published: 2013

Includes: Supplemental data

Journal Articles

Dual Antitumoral and Bone Antiresorptive Effect Of The Pan-Pim Kinase Inhibitor, LGH447, In Multiple Myeloma

Teresa Paíno, Antonio Garcia-Gomez, Lorena González-Méndez, Laura San-Segundo, Montserrat Martín-Sánchez, Susana Hernández-García, Mercedes Garayoa, Enrique M. Ocio, Jesús F. San-Miguel

Blood (2013) 122 (21): 4435.

https://doi.org/10.1182/blood.V122.21.4435.4435

Published: 2013

Journal Articles

Preclinical Efficacy of the Investigational Orally Bioavailable Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

Antonio Garcia-Gomez, Dalia Quwaider, Enrique M Ocio, MD, PhD, Laura San-Segundo, Teresa Paíno, Juan F Blanco, Allison J Berger, PhD, Atanasio Pandiella, MD, PhD, Jesús F San-Miguel, MD, PhD, Mercedes Garayoa

Blood (2012) 120 (21): 4014.

https://doi.org/10.1182/blood.V120.21.4014.4014

Published: 2012

Journal Articles

Phenotypic, Functional and Circadian Characterization of Peripheral Blood (PB) Multiple Myeloma (MM) Circulating Tumor Cells (CTCs)

Bruno Paiva, Teresa Paíno, Mercedes Garayoa, Laura San-Segundo, Montserrat Martin, Maria Luz Sanchez, Paloma Barcena, Luis Corchete, Enrique M Ocio, MD, PhD, Maria Victoria Mateos, MD, PhD, María-Belén Vidriales, Alberto Orfao, Jesus F. San Miguel, MD, PhD

Blood (2012) 120 (21): 726.

https://doi.org/10.1182/blood.V120.21.726.726

Published: 2012

Journal Articles

Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM

Enrique M Ocio, Diego Fernández-Lázaro, Laura San-Segundo, Lorena González-Méndez, Montserrat Martín-Sánchez, Mercedes Garayoa, Teresa Paíno, Antonio Garcia-Gomez, Norma C. Gutierrez, Manuel Delgado, Juan C. Montero, Nuria Quintana, Jose Luis García, Atanasio Pandiella, Jesús F. San Miguel, MD, PhD

Blood (2011) 118 (21): 134.

https://doi.org/10.1182/blood.V118.21.134.134

Published: 2011

Journal Articles

A Novel Murine Model of Human Disseminated Multiple Myeloma with A Subcutaneous Human Bone Chip from an Adult Donor Confers Proliferative Advantage and Is Suitable for the In Vivo Evaluation of Novel Drugs

Enrique M. Ocio, Laura San-Segundo, Juan Blanco, Teresa Hernández-Iglesias, Diego Fernández-Lázaro, Teresa Paíno, Mercedes Garayoa, Enrique Álava, Fernando Jiménez-Barredo, Elena Díaz-Rodríguez, Atanasio Pandiella, J.F San Miguel

Blood (2010) 116 (21): 4077.

https://doi.org/10.1182/blood.V116.21.4077.4077

Published: 2010

Journal Articles

Zalypsis Has Synergistic Effect When Combined with Bortezomib + Dexamethasone through Caspase Dependent and Mainly Independent Mechanisms and through A Potent Induction of DNA Damage

Enrique M. Ocio, Lorena González-Coco, Laura San-Segundo, Xi Chen, Teresa Hernández-Iglesias, Diego Fernández-Lázaro, Teresa Paíno, Mercedes Garayoa, Carmen Cuevas, Pablo Avilés, Enrique Álava, Atanasio Pandiella, J.F San Miguel

Blood (2010) 116 (21): 3003.

https://doi.org/10.1182/blood.V116.21.3003.3003

Published: 2010

Journal Articles

Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease.

Antonio Garcia-Gomez, Mercedes Garayoa, Enrique M. Ocio, Edvan Crusoe, Diego Fernández, Teresa Paíno, Laura San Segundo, Juan C. Montero, Stela Álvarez-Fernández, Juan F. Blanco, Fermin M. Sanchez-Guijo, Felix T. Garzon, Atanasio Pandiella, Jesús F. San-Miguel, MD, PhD

Blood (2009) 114 (22): 3834.

https://doi.org/10.1182/blood.V114.22.3834.3834

Published: 2009

Journal Articles

Zalypsis Possess Potent Antileukemic Effect through the Induction of a DNA Damage Response, Independently of the p53 Status.

Enrique Colado, Teresa Paíno, Enrique M Ocio, Patricia Maiso, Xi Chen, Stela Álvarez-Fernández, Jesús Martín-Sánchez, Lorena González, Laura San-Segundo, Mercedes Garayoa, Diego Fernández-Lázaro, Maria-Belén Vidriales, Carlos Galmarini, Pablo Avilés, Carmen Cuevas, Atanasio Pandiella, Jesús F. San-Miguel, MD, PhD

Blood (2009) 114 (22): 3792.

https://doi.org/10.1182/blood.V114.22.3792.3792

Published: 2009

Journal Articles

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks

Enrique M. Ocio, Patricia Maiso, Xi Chen, Mercedes Garayoa, Stela Álvarez-Fernández, Laura San-Segundo, David Vilanova, Lucía López-Corral, Juan C. Montero, Teresa Hernández-Iglesias, Enrique de Álava, Carlos Galmarini, Pablo Avilés, Carmen Cuevas, Jesús F. San-Miguel, Atanasio Pandiella

Blood (2009) 113 (16): 3781–3791.

https://doi.org/10.1182/blood-2008-09-177774

Published: 2009

Includes: Supplemental data

Journal Articles

DNA Double Strand Breaks Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity

Enrique M Ocio, Patricia Maiso, Xi Chen, Mercedes Garayoa, Stela Álvarez-Fernández, Laura San-Segundo, David Vilanova, Lucía López-Corral, Juan Carlos Montero, Teresa Hernández-Iglesias, Enrique de Álava, Carlos Galmarini, Pablo Avilés, Carmen Cuevas, Atanasio Pandiella, J.F. San Miguel, MD, PhD

Blood (2008) 112 (11): 245.

https://doi.org/10.1182/blood.V112.11.245.245

Published: 2008

Journal Articles

Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model.

Enrique M. Ocio, MD, PhD, David Vilanova, BS, Laura San-Segundo, BS, Patricia Maiso, BS, PhD, Mercedes Garayoa, BS, PhD, Peter Atadja, Atanasio Pandiella, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2007) 110 (11): 1514.

https://doi.org/10.1182/blood.V110.11.1514.1514

Published: 2007

NARROW

Antimyeloma Effect of the Simultaneous Inhibition of MCL-1 (with S63845) and BCL-2 (with Venetoclax) in the Presence of the Microenvironment

CRISPR/Cas9-Generated Models Uncover Therapeutic Vulnerabilities of Del(11q) Chronic Lymphocytic Leukemia Cells to Dual BCR and PARP Inhibition

Prognostic Implications of PIM-2 Expression in Samples from Patients with Chronic Lymphocytic Leukemia and Impact in the Sensitivity to the Pan-PIM Kinase Inhibitor PIM447

Mechanisms Underlying the Synergistic Interaction of Filanesib with Pomalidomide and Dexamethasone (FPD) in Multiple Myeloma

Filanesib Primarily Initiates the Apoptotic Program By Activating Bax through a Calpain-Dependent Mechanism

The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone

The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies

Filanesib (ARRY-520) Demonstrates Potent and Rapid Activity in Preclinical Models of MM, Dependent on Bcl-2 Family Expression, and Synergistic with Dexamethasone and IMiDs

Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile

Dual Antitumoral and Bone Antiresorptive Effect Of The Pan-Pim Kinase Inhibitor, LGH447, In Multiple Myeloma

Preclinical Efficacy of the Investigational Orally Bioavailable Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

Phenotypic, Functional and Circadian Characterization of Peripheral Blood (PB) Multiple Myeloma (MM) Circulating Tumor Cells (CTCs)

Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM

A Novel Murine Model of Human Disseminated Multiple Myeloma with A Subcutaneous Human Bone Chip from an Adult Donor Confers Proliferative Advantage and Is Suitable for the In Vivo Evaluation of Novel Drugs

Zalypsis Has Synergistic Effect When Combined with Bortezomib + Dexamethasone through Caspase Dependent and Mainly Independent Mechanisms and through A Potent Induction of DNA Damage

Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease.

Zalypsis Possess Potent Antileukemic Effect through the Induction of a DNA Damage Response, Independently of the p53 Status.

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks

DNA Double Strand Breaks Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity

Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only